Cargando…

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angi...

Descripción completa

Detalles Bibliográficos
Autores principales: Giampieri, Riccardo, Salvatore, Lisa, Del Prete, Michela, Prochilo, Tiziana, D’Anzeo, Marco, Loretelli, Cristian, Loupakis, Fotios, Aprile, Giuseppe, Maccaroni, Elena, Andrikou, Kalliopi, Bianconi, Maristella, Bittoni, Alessandro, Faloppi, Luca, Demurtas, Laura, Montironi, Rodolfo, Scarpelli, Marina, Falcone, Alfredo, Zaniboni, Alberto, Scartozzi, Mario, Cascinu, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846860/
https://www.ncbi.nlm.nih.gov/pubmed/27117754
http://dx.doi.org/10.1038/srep25195
_version_ 1782429116767666176
author Giampieri, Riccardo
Salvatore, Lisa
Del Prete, Michela
Prochilo, Tiziana
D’Anzeo, Marco
Loretelli, Cristian
Loupakis, Fotios
Aprile, Giuseppe
Maccaroni, Elena
Andrikou, Kalliopi
Bianconi, Maristella
Bittoni, Alessandro
Faloppi, Luca
Demurtas, Laura
Montironi, Rodolfo
Scarpelli, Marina
Falcone, Alfredo
Zaniboni, Alberto
Scartozzi, Mario
Cascinu, Stefano
author_facet Giampieri, Riccardo
Salvatore, Lisa
Del Prete, Michela
Prochilo, Tiziana
D’Anzeo, Marco
Loretelli, Cristian
Loupakis, Fotios
Aprile, Giuseppe
Maccaroni, Elena
Andrikou, Kalliopi
Bianconi, Maristella
Bittoni, Alessandro
Faloppi, Luca
Demurtas, Laura
Montironi, Rodolfo
Scarpelli, Marina
Falcone, Alfredo
Zaniboni, Alberto
Scartozzi, Mario
Cascinu, Stefano
author_sort Giampieri, Riccardo
collection PubMed
description Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angiogenesis and thus potentially influence outcome during anti-angiogenesis treatment such as regorafenib. Aim of our study was to evaluate the role of VEGF and VEGFR genotyping in determining clinical outcome for colorectal cancer patients receiving regorafenib. We retrospectively collected clinical data and samples (tumour or blood) of 138 metastatic colorectal cancer patients treated with regorafenib. We analysed the correlation of different VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs) with patients’ progression-free survival (PFS) and overall survival (OS). Results from angiogenesis genotyping showed that only VEGF-A rs2010963 maintained an independent correlation with PFS and OS. Among clinical factors only ECOG PS was independently correlated with OS, whereas no correlation with PFS was evident. Grouping together those results allowed further patients stratification into 3 prognostic groups: favourable, intermediate and unfavourable. VEGF-A rs2010963 genotyping may represent an important tool for a more accurate selection of optimal candidates for regorafenib therapy.
format Online
Article
Text
id pubmed-4846860
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48468602016-05-04 Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients Giampieri, Riccardo Salvatore, Lisa Del Prete, Michela Prochilo, Tiziana D’Anzeo, Marco Loretelli, Cristian Loupakis, Fotios Aprile, Giuseppe Maccaroni, Elena Andrikou, Kalliopi Bianconi, Maristella Bittoni, Alessandro Faloppi, Luca Demurtas, Laura Montironi, Rodolfo Scarpelli, Marina Falcone, Alfredo Zaniboni, Alberto Scartozzi, Mario Cascinu, Stefano Sci Rep Article Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angiogenesis and thus potentially influence outcome during anti-angiogenesis treatment such as regorafenib. Aim of our study was to evaluate the role of VEGF and VEGFR genotyping in determining clinical outcome for colorectal cancer patients receiving regorafenib. We retrospectively collected clinical data and samples (tumour or blood) of 138 metastatic colorectal cancer patients treated with regorafenib. We analysed the correlation of different VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs) with patients’ progression-free survival (PFS) and overall survival (OS). Results from angiogenesis genotyping showed that only VEGF-A rs2010963 maintained an independent correlation with PFS and OS. Among clinical factors only ECOG PS was independently correlated with OS, whereas no correlation with PFS was evident. Grouping together those results allowed further patients stratification into 3 prognostic groups: favourable, intermediate and unfavourable. VEGF-A rs2010963 genotyping may represent an important tool for a more accurate selection of optimal candidates for regorafenib therapy. Nature Publishing Group 2016-04-27 /pmc/articles/PMC4846860/ /pubmed/27117754 http://dx.doi.org/10.1038/srep25195 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Giampieri, Riccardo
Salvatore, Lisa
Del Prete, Michela
Prochilo, Tiziana
D’Anzeo, Marco
Loretelli, Cristian
Loupakis, Fotios
Aprile, Giuseppe
Maccaroni, Elena
Andrikou, Kalliopi
Bianconi, Maristella
Bittoni, Alessandro
Faloppi, Luca
Demurtas, Laura
Montironi, Rodolfo
Scarpelli, Marina
Falcone, Alfredo
Zaniboni, Alberto
Scartozzi, Mario
Cascinu, Stefano
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
title Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
title_full Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
title_fullStr Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
title_full_unstemmed Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
title_short Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
title_sort angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846860/
https://www.ncbi.nlm.nih.gov/pubmed/27117754
http://dx.doi.org/10.1038/srep25195
work_keys_str_mv AT giampieririccardo angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT salvatorelisa angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT delpretemichela angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT prochilotiziana angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT danzeomarco angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT loretellicristian angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT loupakisfotios angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT aprilegiuseppe angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT maccaronielena angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT andrikoukalliopi angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT bianconimaristella angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT bittonialessandro angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT faloppiluca angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT demurtaslaura angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT montironirodolfo angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT scarpellimarina angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT falconealfredo angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT zanibonialberto angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT scartozzimario angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients
AT cascinustefano angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients